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Summary
Breast tissue from healthy women contains variant mammary epithelial cells (vHMEC) exhibiting p16INK4a promoter hyper-
methylation both in vivo and in vitro. When continuously cultured, vHMEC acquire telomeric dysfunction and produce the
types of chromosomal abnormalities seen in premalignant lesions of cancer. We find that late passage vHMEC express
elevated prostaglandin cyclo-oxygenase 2 (COX-2), which contributes to increased prostaglandin synthesis, angiogenic
activity, and invasive ability. These data demonstrate the existence of human mammary epithelial cells with the potential
to acquire multiple genomic alterations and phenotypes associated with malignant cells. Moreover, COX-2 overexpression
coincides with focal areas of p16INK4a hypermethylation in vivo, creating ideal candidates as precursors to breast cancer.
These putative precursors can be selectively eliminated upon exposure to COX-2 inhibitors in vitro.
Introduction et al., 2001; Tlsty et al., 2001). In a recent study, we found
that a subpopulation of histologically normal human mammary
Breast tissue from healthy women, when examined in vitro, tissues in vivo also contains cells with hypermethylated p16INK4a
contains a subpopulation of variant mammary epithelial cells promoter sequences. These cells were found in discrete foci in
(vHMEC, postselection, M0, or postsenescent HMEC) that have a substantial fraction of women with no indication or predisposi-
silenced p16INK4a through hypermethylation of promoter se- tion to breast cancer (Holst et al., 2003). We hypothesize that
quences (Brenner et al., 1998; Foster et al., 1998; Huschtscha et this subpopulation of vHMEC, which exists in vivo, has potential
al., 1998). These cells exhibit several properties that distinguish for progression to premalignant and ultimately malignant lesions
them from the majority of mammary epithelial cells that prolifer- of the breast. Therefore, characterization of these cells in vitro
ate from a tissue explant (HMEC or preselection HMEC), includ- may provide molecular markers for identifying premalignant le-
sions of breast cancer in vivo as well as critical targets foring the silencing of p16INK4a gene expression through promoter
hypermethylation and the stabilization of p53 (Romanov et al., therapeutic or preventive intervention.
In this study, we find that cyclo-oxygenase 2 (COX-2), a2001). In culture, vHMEC proliferate an additional 30 to 50 gener-
ations beyond the time that the HMEC population activates a gene that is often overexpressed in many human cancers and
contributes to colon cancer initiation and progression in murineproliferative arrest before reaching a second population growth
plateau, termed agonescence (Romanov et al., 2001). Remark- models (Oshima et al., 1996), is upregulated in p16INK4a hyper-
methylated mammary epithelia in vitro. This upregulation ofably, nearly 100% of vHMEC approaching agonescence exhibit
telomeric dysfunction and acquire chromosomal defects, in- COX-2 contributes to increased prostaglandin synthesis, in-
creased endothelial cell invasion, and invasive ability in vHMECcluding aneuploidy, telomeric associations, and various other
classes of structural abnormalities similar to those seen in the and thus provides growth advantages to already genomically
unstable cells. Ominously, we found that cells with p16INK4a pro-earliest lesions of breast cancer (Holst et al., 2003; Romanov
S I G N I F I C A N C E
Our studies provide molecular markers for identifying perhaps the earliest lesions of human breast cancer (i.e., premalignant
mammary epithelial cells) and a molecular mechanism for their generation. Furthermore, our data indicate that these vHMEC with
malignant phenotypes can be selectively eliminated, thus preventing their further progression. Finally, our study suggests that
nonsteroidal antiinflammatory drugs (NSAIDs) can directly target epithelial cells for cancer prevention in addition to their effect in
targeting stromal and inflammatory cells. These data point to a possible molecular mechanism through which NSAIDs reduce breast
cancer risk.
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moter hypermethylation and coincident intense COX-2 expres-
sion exist in histologically normal human tissues in vivo, creating
ideal candidates for breast cancer precursors.
Results
Human mammary epithelial cells in agonescence
express high levels of COX-2
To identify novel properties that distinguish vHMEC from HMEC,
we compared the gene expression profiles of both cell popula-
tions as they progressed through increasing population dou-
blings using microarrays. Primary explants from reduction mam-
moplasties from women ranging in age from 16 to 57 years
were cultured as described previously to generate the growth
curves for HMEC and vHMEC (Figure 1A). For this study, RNAs
from cells at different passages in culture were compared to
identify markers that change as the cells approach agonescence
(Figure 1A). Among the genes that were upregulated in vHMEC
at later passage or agonescence was COX-2 (an6-fold induc-
tion between late and early vHMEC, Figure 1A, inset). This gene
was of immediate interest, since several lines of evidence impli-
cate COX-2 protein as an important modulator of tumor progres-
sion (Howe et al., 2001). We verified that the upregulation of
COX-2 mRNA was indeed accompanied by an increase in pro-
tein expression via Western blot analysis (Figure 1B) and immu-
nocytochemistry (Figure 1C). In these analyses, COX-2 expres-
sion was undetectable in the early HMEC population but
increased significantly as vHMEC populations approached and
entered agonescence (Figures 1B and 1C). Similar COX-2
upregulation in vHMEC was observed in samples derived from
three additional individuals (Figure 1C and microarray data not
shown). In a fifth case, low levels of COX-2 expression were
observed in HMEC (RM9), and vHMEC from the same mam-
moplasty demonstrated similar COX-2 expression to that of the
other vHMEC populations.
We further investigated the timing, heterogeneity, and level
of COX-2 overexpression in individual vHMEC cells. Immunocy-
tochemical analysis demonstrated that, while COX-2 was ex- Figure 1. COX-2 expression is elevated in vHMEC in vitro
pressed at a high level in the majority of vHMEC at late passage, A: Representative HMEC/vHMEC 48 growth curve. Filled red circles indicate
the protein was expressed at a similarly high level but in far population doublings (PD) at which mRNA was isolated for microarray ex-
periment. Inset: An example of microarray data showing the upregulationfewer cells in vHMEC populations at early passage. Thus, the
of COX-2 (arrow and red color).majority of the increase in COX-2 expression was the result of
B: Expression of human COX-2 protein quantity assessed by Western blotthe induction of an increased number of cells exhibiting high
analysis. The following lysates from HMEC/vHMEC 48 were loaded: HMEC
expression (Figure 1C, right column) rather than a general in- (PD 3), early passage vHMEC (PD 21), mid passage vHMEC (PD 34), and
crease in all cells. These data indicate that the loss of p16INK4a late passage vHMEC (PD 44). The following lysates from HMEC/vHMEC RM16
were loaded: HMEC (PD 4), early passage vHMEC (PD 18), and late passageprotein per se is not responsible for the induction of COX-2,
vHMEC (PD 38).since all early vHMEC cells in the population exhibit p16INK4a
C: Immunocytochemistry for COX-2 expression in HMEC, early, and late
promoter hypermethylation, but only a few cells overexpress passage vHMEC 240 (PD 3, PD 25, and PD 46), RM15 (PD 3, PD 19, and PD
COX-2. Furthermore, expression of exogenous p16 protein in 48), and RM16 (PD 3, PD 13, and PD 44), respectively.
vHMEC overexpressing COX-2 does not suppress COX-2 over-
expression (data not shown). Taken together, these data sug-
gest that the lack of p16 activity may be permissive for a subse-
quent event, which then leads to the induction of COX-2 sion is the increase in the number of cells exhibiting telomeric
overexpression. Once this subsequent event occurs, the conse- dysfunction (Figure 2A). Numerous studies have described how
quences cannot be suppressed by p16 expression. telomeric dysfunction can activate DNA damage response path-
ways (de Lange, 2002; Nautiyal et al., 2002). Therefore, we
investigated the possibility that DNA damage signals such asHigh levels of COX-2 expression can be induced
by DNA damage associated with those generated by telomeric dysfunction could induce COX-2.
To experimentally induce a DNA damage response that mimicstelomeric dysfunction
An event that occurs subsequent to the loss of p16 protein telomeric dysfunction, we exposed early passage vHMEC (with
negligible COX-2 expression) to adriamycin, which was pre-activity and coincides with the increase in COX-2 overexpres-
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Figure 2. DNA damage induces COX-2 expres-
sion
A: Percent COX-2-positive vHMEC (48) increases
as percent vHMEC exhibiting telomere associa-
tion (TAS) increases. Percent COX-2-positive cells
was determined using flow cytometry. TAS was
scored as dicentric telomeres after G-banding
karyotyping.
B–D: Flow analysis indicates that DNA-damaging
agents adriamycin (1 M), campothecin (2.5
M), and etoposide (2.5 M) induce COX-2 ex-
pression. Early vHMEC (RM16, PD 13, or PD 18)
were incubated with adriamycin for 2 hr and with
campothecin or etoposide for 6 hr and analyzed
24 hr later.
viously reported to cause telomeric dysfunction and result in compared to HMEC expressing a negligible level of COX-2 in
an assay for inducing angiogenic ability (Figure 3C, black bars)telomere-related chromosomal abnormalities in breast tumor
cells (Elmore et al., 2002). We found that early passage vHMEC in three vHMEC populations tested (RM15, RM16, and 48).
Finally, vHMEC expressing a high level of COX-2 induced in-exhibited a strong induction of COX-2 expression upon expo-
sure to 1 M adriamycin (Figure 2B). Additionally, we exposed creased invasion of mammary epithelial cells across a Boyden
chamber barrier when compared to HMEC expressing a negligi-early passage vHMEC to inhibitors for topoisomerases I and II
(campothecin and etoposide, respectively), two agents that also ble level of COX-2 (Figure 3D, black bars) in three vHMEC popu-
lations tested (RM15, RM16, and 48). Hence, both vHMEC andgenerate DNA breaks similar to those produced by telomeric
dysfunction (i.e., dicentric chromosomal breakage). Under both tumor cells, each overexpressing COX-2, exhibit similar pheno-
types that contribute to malignant potential. Interestingly, condi-of these conditions, COX-2 was induced in a dose-dependent
manner (Figures 2C and 2D and data not shown). A recent study tioned media from the COX-2-overexpressing vHMEC did not
demonstrate an ability to induce either HUVEC or mammarydemonstrated that DNA damage, induced by mitomycin C, also
upregulates COX-2 (Han et al., 2002). Taken together, our data epithelial cell invasion across a collagen layer (Figures 3C and
3D, white bars). These data suggest that the downstream sig-support the interpretation that DNA damage similar to that pro-
duced by telomeric dysfunction, an event that occurs in vHMEC nal(s) of COX-2 that mediates both angiogenic and invasive
activity is transient or short lived. Thus, constant COX-2 activitysubsequent to p16INK4a promoter hypermethylation, can contrib-
ute to the induction of COX-2 overexpression. is required for the invasive phenotype induced by vHMEC.
To determine if the specific expression of COX-2 is neces-
sary and/or sufficient for the exhibition of these malignant phe-High levels of COX-2 expression in agonescent vHMEC
notypes, we manipulated COX-2 levels and documented theconfers malignant phenotypes
causal relationship between the two events. To remove elevatedWhile the downstream effects of overexpressing COX-2 in tumor
COX-2 expression from late passage vHMEC, we used both acells are well established, the phenotypes that accompany
chemical inhibitor and a COX-2 antisense construct. We ex-COX-2 overexpression in vHMEC are unknown. Comparison of
vHMEC expressing a high level of COX-2 to those with a negligi- posed the late passage vHMEC to a specific COX-2 inhibitor,
NS-398, for 24 hr and measured HUVEC invasion 12 hr later.ble level revealed significant differences in the expression of
phenotypes hypothesized to be critical to malignancy (e.g., con- We found that the originally observed HUVEC invasion (Figure
3C) was substantially reduced upon exposure to NS-398 (Figuretrol of prostaglandin synthesis, angiogenesis, invasion, and apo-
ptosis). vHMEC expressing a high level of COX-2 demonstrated 4A). We next introduced a COX-2 antisense construct under the
control of tetracycline promoter into late vHMEC overexpressinga dramatic increase in the induction of prostaglandin E2 (PGE2),
a direct product of COX-2 activity, as well as three other down- COX-2 (RM16, PD 38; 48, PD 48). Four days after the addition
of doxycycline, COX-2 protein levels were reduced in vHMECstream products of COX-2 (6-keto PGF1, PGF2, and thrombox-
ane B2 [TXB2]) when compared to cells expressing a negligible containing a COX-2 antisense construct (Figure 4E, top panel).
Furthermore, this reduction in COX-2 protein level was accom-level of COX-2 (Figures 3A and 3B and data not shown) (RM16
and 48). Furthermore, vHMEC expressing a high level of COX-2 panied by a reduced level of excreted PGE2 (Figure 4B). When
these cells (RM16 and 48) were assayed for their ability to stimu-stimulated a significant increase in the invasion of human umbili-
cal vein endothelial cells (HUVEC) across a collagen layer when late HUVEC invasion or movement of vHMEC across transwell
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(Supplementary Figure S2). Furthermore, the HLA-1 protein level
was similar in cells expressing either a COX-2 antisense or
the vector control (Supplementary Figure S3), and the growth
kinetics (or population doublings) (Supplementary Figure S4)
for vHMEC containing either a COX-2 antisense or a control
construct remain the same after the induction of COX-2 anti-
sense expression for a period of time, including the 4 days
during which all the relevant experiments were done. Together,
our data indicate that COX-2 plays a causal role in the induction
of these phenotypes observed in late vHMEC.
To investigate the sufficiency of COX-2 in promoting the
phenotypes observed, we introduced exogenous COX-2 into
early vHMEC (RM15, PD 7; RM16, PD 10; and 48, PD 10) that
exhibited a low level of endogenous COX-2 expression (Figure
4E, bottom panel). This increase in COX-2 protein level was
accompanied by an increased level of excreted PGE2 (Figure
4F), and we found an increase in HUVEC and vHMEC invasion
phenotypes (Figures 4G and 4H) in all three vHMEC populations
tested (RM15, RM16, and 48; only data for RM15 is shown).
Interestingly, early vHMEC expressing exogenous COX-2 often
demonstrated only a modest increase in the HUVEC and vHMEC
invasion phenotypes when compared to late passage vHMEC
overexpressing endogenous COX-2 (Figure 3C), despite the factFigure 3. Late passage COX-2-overexpressing vHMEC exhibit increased
PGE2 production, angiogenic potential, and invasive ability that their COX protein levels were similar (data not shown).
A: Fold induction in PGE2 levels. PGE2 levels were determined using ELISA These data suggest that early vHMEC but not late vHMEC may
assay (Cayman Chemical) and normalized to the number of cells (RM16) still maintain the ability to modulate COX-2-mediated pheno-
harvested. The level of PGE2 for HMEC was set to be 1. Fold of PGE2 induction types. Nevertheless, our data suggest that COX-2 overexpres-
for vHMEC was determined as the ratio of PGE2 levels for vHMEC versus sion alone is able to increase the HUVEC and vHMEC invasionHMEC (mean  SEM). RM16 HMEC and early and late vHMEC were at PD
phenotype. Together, our data demonstrate that COX-2 overex-5, PD 20, and PD 43, respectively.
B: PGE2 concentration in media (determined using mass spectrometry at pression in late vHMEC is causal for the phenotypes that pro-
Vanderbilt University) increases as vHMEC (RM16 p4 or PD 20, p8 or PD 34, mote malignant potential.
and p11 or PD 43) approach agonesence.
C: Late passage vHMEC (RM16) but not conditioned media from late pas-
Foci of histologically normal human mammary epitheliasage vHMEC exhibit increased ability to summon HUVEC. “c” (black bar),
experiment was done with HMEC or vHMEC. “cm” (white bar), conditioned with p16INK4a promoter methylation overexpress
media was used for the experiment. COX-2 in vivo
D: Late passage vHMEC (RM16) but not conditioned media from late pas- Our previous work identified focal aggregates of mammary epi-
sage vHMEC exhibit increased ability to induce mammary epithelial cell
thelial cells that contained methylated p16INK4a promoter se-invasion across a collagen layer. RM16 HMEC/vHMEC p1, p2, p7, p11, and
quences in a subgroup of reduction mammoplasties obtainedp13 were at PD 2, PD 13, PD 30, PD 44, and PD 49, respectively.
All experiments in C–D were done in triplicate, and all data were normalized from healthy women (Holst et al., 2003). As reported here, in vitro
to the number of cells harvested. Data obtained for HMEC or conditioned cultured vHMEC with methylated p16INK4a promoter sequences
media from HMEC within each experiment were set to be 1, and fold induc- have the ability not only to accumulate chromosomal abnormali-tion for vHMEC were determined as the ratio of vHMEC versus HMEC
ties but also to induce malignant phenotypes by upregulating(mean  SEM).
COX-2. These cells would be ideal candidates for precursors
to premalignant lesions of breast cancer, an observation that
provoked our search for these cells in vivo. As reported earlier,
cells within histological sections containing the methylatedbarrier, both phenotypes were substantially attenuated, drop-
p16INK4a promoter sequences retained normal tissue architec-ping to the same levels observed after exposure to NS-398
ture, as confirmed by hemotoxylin and eosin (H&E) staining of(Figures 4C and 4D). Expression of an antisense RNA may trigger
adjacent serial sections (Holst et al., 2003). Strikingly, COX-2an interferon response as a consequence of dsRNA formation
staining of the adjacent serial sections demonstrated that onlyand an altered pattern of protein expression. To exclude the
samples with foci containing ductal or lobular epithelial cellspossibility that the activation of an interferon response caused
with p16INK4a promoter hypermethylation (yellow areas, Figurethe reduction in the phenotypes observed above, we induced
5) exhibited intense COX-2 staining (red demarcations, Figurean interferon response in our vHMEC cells (RM15, PD 25; RM
5, samples 9698 and 9624). This colocalization of COX-2 protein16, PD 30) by exposing them to human interferon . We found
staining and p16INK4a promoter hypermethylation within the samethat the addition of interferon  (5–100 unit/ml) for 2–6 days
cells is presented in a recently described mapping techniquewas sufficient to upregulate the expression of a cell surface
(Figure 5 and Holst et al., 2003), and examples of COX-2 stainingprotein, HLA-1, as previously reported (Satoh et al., 1995) (see
are shown. In some places, the areas of intense COX-2 stainingSupplementary Figure S1 at http://www.cancercell.org/cgi/
content/full/5/3/263/DC1). However, despite the activation of are seen beyond the individual ducts and lobules that contain
luminal mammary epithelial cells with hypermethylation ofinterferon response in these vHMECs, neither HUVEC invasion
nor movement of vHMEC across transwell barrier was reduced p16INK4a promoter sequences in the surrounding epithelial struc-
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Figure 4. COX-2 contributes to the phenotypes
observed in late vHMEC
A: COX-2 specific inhibitor NS-398 (25 M) re-
duces the angiogenic activity in late vHMEC
(RM16, PD 44). The experiment was carried out
as above except that DMSO or NS-398 in DMSO
was added to the media 24 hr before the assay.
Data obtained for DMSO control was set to be
1, and fold change for vHMEC in NS-398 was
determined as the ratio of vHMEC/NS-398 versus
vHMEC/DMSO. Note: addition of NS-398 (25 M)
did not kill vHMEC within the 36 hr period expo-
sure time.
B–D: Expression of COX-2 antisense RNA reduces
PGE2 level and reduced HUVEC and vHMEC in-
vasion phenotypes, respectively, in late vHMEC
(RM16, PD 44).
E: The top panel shows Western blot analysis for
COX-2 protein level in late vHMEC with either
vector control or COX-2 antisense with or without
the addition of Doxycycline (RM16, PD 44). (Bot-
tom panel) Western blot analysis for COX-2 pro-
tein level in early vHMEC (RM15, PD 7) with either
vector or COX-2 overexpression construct.
F–H: Overexpression of COX-2 leads to increased
PGE2 level and increased HUVEC and vHMEC
invasion phenotypes, respectively, in early
vHMEC (RM15, PD 7). Similar results were ob-
served with other RMs.
tures. This is possibly due to the diffusion of COX-2 products 1998), for 5 days and assayed its effect on viability. As shown
in Figures 6A–6C, vHMEC that expressed high levels of COX-2(e.g., prostaglandins) to the immediately adjacent areas, which
upregulate COX-2 expression (Tjandrawinata and Hughes-Ful- protein exhibited a significant decline in viability and activation
of apoptosis as demonstrated by TUNEL analysis (Figure 6B).ford, 1997). Alternatively, this may be due to an underestimate
of the number of ducts and lobules that contain cells with hyper- Upon exposure of the cells to NS-398 for 5 days, the majority
of late passage vHMEC died, while, under identical conditions,methylated p16INK4a promoter sequences. The mammary tissue
that expresses high COX-2 levels may have hypermethylation the majority of the (non-COX-2-overexpressing) HMEC re-
mained viable (Figures 6A–6C). This analysis was performed onof adjacent CpG islands that are beyond the region of the p16INK4a
promoter sequences we investigated via methylation-specific four isogenic sets of HMEC and vHMEC with similar results
(RM15, RM16, 48, and 240).PCR. In one sample, 10811, COX-2 staining was less intense
than that observed in the other two samples with p16INK4a silenc- It has often been observed that therapeutic agents that are
effective in two-dimensional assays may be ineffective whening (Figure 5, sample 10811). This may reflect a cell population
that has not yet fully sustained the events subsequent to p16INK4a the cells are grown in three-dimensional structures (Hoffman,
promoter hypermethylation that allow for full COX-2 induction 1993). To better assess the potential of COX-2 inhibitors in
or, alternatively, a cell population that has processed the events vivo, we suspended HMEC and vHMEC (RM16 and 240) in
so that they no longer induce COX-2. Low to undetectable reconstituted basement membrane, where they formed three-
expression of COX-2 was observed in the majority of the tissue dimensional structures (mammospheres), and exposed these
from the seven samples that were devoid of p16INK4a promoter mammospheres to NS-398. Our results demonstrate that even
hypermethylation. Expression of COX-2 was largely devoid in when in three-dimensional structures, the COX-2 inhibitor effec-
surrounding stromal areas independent of p16INK4a promoter tively killed the COX-2-overexpressing vHMEC while having a
hypermethylation status in the epithelial cells. These data dem- negligible effect on HMEC (Figure 6D).
onstrate that foci of vHMEC in vivo exhibit elevated COX-2
expression. Discussion
In vivo foci of histologically normal mammary epithelialvHMEC with high levels of COX-2 expression apoptose
when exposed to a COX-2 inhibitor both in two- cells have silenced a tumor suppressor and
activated a tumor-promoting programdimensional culture and in three-dimensional
mammospheres Excitingly, our studies identify an in vivo population of mammary
epithelial cells in disease-free women that have the ability toThese newly described attributes of vHMEC have important
clinical implications. Since COX-2 is known to inhibit apoptosis, silence the tumor suppressor gene p16INK4a through promoter
hypermethylation and overexpress the tumor-promoting geneinhibition of COX-2 functions may reinstate the apoptotic re-
sponse and curtail the expansion of cells overexpressing COX-2. Our studies also identify an in vitro population of variant
mammary epithelial cells from disease-free women that, by lossCOX-2. To this end, we exposed HMEC and vHMEC to various
concentrations of NS-398, a specific COX-2 inhibitor (Liu et al., of certain cell cycle checkpoint controls, have the ability to
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Figure 5. Intense COX-2 staining coincides with
focal areas of p16INK4a promoter hypermethyla-
tion in histologically normal tissue in vivo
Aa–Aj: We generated a gridded map of epithe-
lial cell clusters by examining the H&E section at
40magnification. All samples were determined
to be histologically normal. Ductal clusters are
illustrated as open ovals, lobular clusters as filled
ovals, and foci of p16INK4a promoter hypermethy-
lation as yellow areas in Aa, Ab, and Ac (samples
9698, 9624, and 10811, respectively). In the adja-
cent serial sections, COX-2 expression level was
qualitatively assessed by immunohistochemical
staining and then scored as intense (red, 50%
cells staining at highest intensity), moderate
(pink, 1%–50% cells staining with heterogene-
ous low to moderate intensity), or low (black,
0%–5% cells staining with low intensity). The ex-
amples of moderate COX-2 staining displayed
in rows four and five are examples of the most
intense staining observed in samples Ad and Ae.
The few epithelial cell clusters that could not be
assessed due to processing problems are gray.
Regions of adipose tissue are not indicated for
simplicity. Samples Aa, 9698; Ab, 9624; and Ac,
10811, each contain areas of p16INK4a promoter
hypermethylation as previously identified by in
situ hybridization detection of methylation-spe-
cific PCR. Samples (Ad–Aj) 10966, 10434, 12075,
11755, 11018, 11139, and 12610, respectively,
were previously determined to be devoid of foci
with p16INK4a promoter hypermethylation. The
arrows indicate representative areas of intense
(I), moderate (M), or low (L) staining for selected
samples within that row. Note that, in the seven
samples that were devoid of p16INK4a promoter
hypermethylation, we did not observe any areas
of intense COX-2 staining. Differential fixation,
processing, and sectioning of clinical specimens
can contribute to heterogeneity of staining and
limits quantitative analysis.
accumulate chromosomal abnormalities and express pheno- least a fraction of premalignant lesions. Our recent finding of
COX-2 overexpression in the majority of ductal carcinoma intypes that are critical to malignant progression. Without inactiva-
tion of pathways that prevent proliferation past a barrier, vHMEC situ (DCIS) lesions lends credence to this hypothesis (Shim et
al., 2003). Even more intriguing was the finding that the histologi-could not proliferate to the point of telomeric crisis and undergo
the sustained subsequent induction of COX-2. Thus, the initial cally normal epithelial cells surrounding DCIS lesions, which
were either positive or negative for COX-2 overexpression, alsocheckpoint control defect, due in part to the epigenetic modula-
tion of p16INK4a, plays a crucial role in funneling cells into malig- demonstrated increased expression of COX-2. These observa-
tions suggest that cells with overexpression of COX-2 may pro-nant pathways. The striking colocalization of COX-2 expression
and p16INK4a promoter hypermethylation within the same cells vide a fertile field for the emergence of premalignant lesions and,
as discussed below, could be excellent targets for preventiveboth in vivo and in vitro emphasizes the relevance of our in vitro
studies in dissecting the early pathways leading to carcinogen- therapy.
esis.
Importantly, these studies also identify therapeutic targets Several of the “hallmarks of cancer” are cocoordinately
controlled by COX-2 expressionthat would allow for the elimination of these variant cells if they
prove relevant to human disease. If variant cells were involved The colocalization of intense COX-2 staining in cells with hyper-
methylated p16INK4a sequences has important implications forin disease progression, one would expect to find them in at
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Figure 6. COX-2 inhibitor reduces cell survival of COX-2-expressing vHMEC
A: Percent survival of HMEC and vHMEC (RM16, PD 4 and PD 34) in the presence of various concentration of NS-398 after 5 days of incubation (mean 
SEM).
B: TUNEL experiment demonstrating the percentage of apoptotic cells after exposure to 25 M NS-398 (RM16, PD 4 and PD 37).
C: Phase image of RM16 HMEC/vHMEC (PD 4 and PD 34) after incubation with 0, 25, and 50 M NS-398 for 5 days.
D: Light microscopy (LM) and propidium iodine (PI) staining of HMEC and vHMEC (sample 240, PD 4 and PD 44) mammospheres in 3D culture after incubation
with 0, 50, and 100 M NS-398 for 5 days. Light microscopy illustrates the disrupted architecture of vHMEC mammospheres after incubation with NS-398. PI
staining (red color) indicates cell death within vHMEC mammospheres after incubation with NS-398.
the initiation and progression of malignancy in breast tissue. tics identified as the hallmarks of cancer (Hanahan and Wein-
berg, 2000) and may represent a bona fide premalignant popula-COX-2 expression has been shown to be accompanied by phe-
notypes that are critically relevant to cancer development (Howe tion. One characteristic these cells do not exhibit is unlimited
replicative potential. In these cells, the loss of p16 allows anet al., 2001), several of which have been designated as “hall-
marks of cancer” (Hanahan and Weinberg, 2000). COX-2 cata- extended proliferative potential but not immortalization. Thus,
we hypothesize that the overexpression of COX-2 enhanceslyzes the production of prostaglandins (PGs), including prosta-
glandin E2 (PDE2), which stimulates mammary epithelial cell their malignant potential, priming them for malignant transfor-
proliferation in the presence of EGF (Bandyopadhyay et al., mation, but additional alterations may be required for full trans-
1987), and estrogen synthesis by activating aromatase (Harris formation.
et al., 1999). COX-2-induced PDE2 also mediates immunosup-
pression by inhibiting T- and B-lymphocytes and cytokine pro- DNA damage and genomic instability lead to the
induction of COX-2 and the activation of stromal andduction (Howe et al., 2001; Huang et al., 1998). Furthermore, the
overexpression of COX-2 in tumor cells regulates angiogenesis, epithelial phenotypes crucial in malignant progression
Genomic instability plays a pivotal role in initiating and promot-invasion, and apoptosis by promoting production of proangio-
genic, proinvasive, and antiapoptotic factors (Gately, 2000; ing the expression of malignant phenotypes on several levels.
In human mammary epithelial cells, the hypermethylation ofTsujii and DuBois, 1995). Therefore, COX-2 expression in human
mammary cells may provide sustained growth signals to mam- p16INK4a promoter sequence abrogates selected cell cycle
checkpoint controls (Meyer et al., 1999) and allows the HMECmary epithelial cells, protection from immune surveillance, and
expression of malignant phenotypes. Our data (Figures 3 and to bypass an in vitro growth barrier whose origin is currently
unknown (Brenner et al., 1998; Romanov et al., 2001) (Figure6) suggest that vHMEC containing hypermethylated p16INK4a pro-
moter sequences and COX-2 overexpression exhibit malignant 7). This loss of p16 protein relieves cyclin D1/cyclin-dependent
kinase 4/6-control during G1/S transition and allows the subse-phenotypes such as increased angiogenesis and invasion and
decreased apoptosis. Thus, they possess several characteris- quent unrestrained phosphorylation of pRB by cdk4/6 (T.D.T,
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dysfunction, DNA damage, and sustained induction of COX-2)
provide a mechanistic framework for malignant transformation.
NSAIDs target overexpression of COX-2 in mammary
epithelia in addition to stroma acting both early
and late in malignant progression
The first convincing evidence linking COX-2 to tumor initiation
and progression came from studies in APC-deficient, COX-2
null mice (Oshima et al., 1996). The lack of COX-2 (either through
genetic or pharmacological manipulation) reduces the incidence
of intestinal adenomas and tumor size (Alshafie et al., 2000;
Harris et al., 2000; Nakatsugi et al., 2000; Robertson et al.,
1998). While the removal of COX-2 function suppresses tumor
initiation and progression, the overexpression of COX-2 exacer-
bates the process in murine models. Oshima et al. provide
genetic evidence that the induction of COX-2 is an early, rate-
limiting step for adenoma formation (Oshima et al., 1996). Fur-
thermore, tissue-specific overexpression of COX-2 from a
mouse mammary tumor virus (MMTV) promoter was sufficient
to cause mammary tumors in multiparous mice (Liu et al., 2001).
These results in murine models strongly suggest that COX-2 is
Figure 7. Genomic instability potentiates premalignant programs an important modulator of both tumor initiation and progression.
p16INK4a promoter sequence hypermethylation allows cells to proliferate until In humans, COX-2 also plays a dual role in carcinogenesis.
acquiring telomeric dysfunction. Genomic instability generated by chromo- The overexpression of COX-2 is often observed in multiple hu-
somal breakage associated with telomeric dysfunction is pivotal in activat-
man tumors, including breast, colon, pancreas, and prostateing multiple phenotypes associated with cancer through the upregulation
(Soslow et al., 2000; Tucker et al., 1999). Additionally, and con-of a single gene, COX-2. COX-2 can also be induced via other pathways
indicated in the figure as X, Y, Z. sistent with our view that COX-2 may play a role in early steps
of carcinogenesis, epidemiological data suggest regular use of
nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin,
which inhibits COX-2, reduces both sporadic and familial colon
unpublished data). In the absence of these restraints and the cancer incidence (Gupta and Dubois, 2001; Thun et al., 1991).
presence of adequate nutrients and mitogenic factors, the Other studies point to a similar NSAID effect for breast and
vHMEC have an extended replicative potential (Brenner et al., pancreatic cancer incidence (Friedman and Ury, 1980; Harris
et al., 1996; Schreinemachers and Everson, 1994; Sharpe et1998; Romanov et al., 2001). As vHMEC further proliferate, they
al., 2000). A recent large prospective cohort study involving overcontinue to erode telomeric sequences until they experience
80,000 postmenopausal women indicated that there was a 21%telomeric dysfunction and initiate a cascade of genomic instabil-
and 28% reduction in the risk of breast cancer for women whoity (Romanov et al., 2001). Telomere dysfunction not only pro-
took NSAIDs at least twice a week for at least 5–10 years whenvides genetic mutations required for cancer initiation (Maser
compared to women who reported no or minimal NSAIDs usageand DePinho, 2002) but also instigates an apoptotic response
(Harris et al., 2003). These data, in conjunction with our observa-(Karlseder et al., 1999). Studies in this report suggest that
tions of histologically normal human tissue in this report andvHMEC with telomere dysfunction may also oppose these death
studies from murine models, suggest that COX-2 functions bothsignals by inducing COX-2, an antiapoptotic regulator, and thus
early and late in tumor progression and highlight COX-2 as aallow the further proliferation of otherwise unviable cells. Con-
potential target for preventive therapy.comitantly, these cells acquire malignant phenotypes that act
within the epithelial cell as well as in the surrounding stroma
Conclusion(i.e., increased angiogenic response). The COX-2-induced inhi-
In summary, we demonstrate intense expression of COX-2 pro-
bition of apoptosis and immune surveillance, along with the
tein colocalized with p16INK4a promoter hypermethylation in hu-
acquisition of invasive abilities, generates a population of epithe- man mammary epithelial cells both in vitro and in vivo. COX-2
lial cells that are poised for malignant progression. Furthermore, expression in these cells parallels the acquisition of telomeric
the COX-2-induced remodeling of the stroma, along with the dysfunction and can be induced by DNA damage. Further,
induction of angiogenesis, supports this malignant program. COX-2 overexpression together with p16INK4a promoter hyper-
Thus, we postulate that the two events of genomic instability, methylation generates critical phenotypes that are believed to
epigenetic modulation of p16INK4a and chromosomal breaks gen- be instrumental in the progression to malignancy. Our data also
erated by telomeric dysfunction, provide the initiating and pro- indicate that NSAIDs can directly target epithelial cells for cancer
moting forces that drive the acquisition of a premalignant pro- prevention in addition to their effect in targeting stromal and
gram (Figure 7). Subsequent induction of COX-2 (and other inflammatory cells. Finally, the identification of differentially ex-
gene alterations) provide growth advantages to these otherwise pressed genes in vHMEC not only allows for the identification
compromised cells. While we do not suggest that all cancers of early lesions of breast cancer but also suggests targets for
arise in this manner, we do suggest that the critical events in the selective removal of these putative precursor cells from the
body.this process (loss of cell cycle checkpoint control, telomere
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Experimental procedures PGE2 measurement
PGE2 was determined using Prostaglandin E2-Monoclonal Enzyme Immuno-
Cells and cell culture assay kit (Cayman Chemical). Each experiment was carried out in triplicate
Isolation and culture of HMEC in modified MCDB 170 (MEGM, BioWhittaker) according to the manufacturer’s protocol.
has been described (Hammond et al., 1984). We studied HMEC/vHMEC from
reduction mammoplasty specimens from five individuals: HMEC/vHMEC 48, Expression of COX-2 sense and antisense constructs
HMEC/vHMEC 240 (kindly provided by Martha Stampfer), HMEC/vHMEC COX-2 sense construct was packaged in Phoenix A cells for viral propaga-
RM9, RM15, and RM16 (cells derived in our laboratory). Population doublings tion. Viral supernatant was diluted 1:1 with MEGM media and then added
(PD) were calculated using the equation PD  log(A/B)/log2, where A is the to the early vHMEC twice consecutively. vHMEC infected with retroviruses
number of cells collected, and B is the number of cells plated. were selected and maintained in 2 g/ml puromycin. The tetracycline-on
gene expression plasmid pUHD.2neo expressing the COX-2 antisense was
Microarray experiment transfected into late vHMECs using Lipofectamine 2000 (Invitrogene). Stable
Total RNA was isolated from HMEC (individual 48) using Qiagen Rneasy clones of vHMEC containing COX-2 antisense construct were selected and
midi kit (Qiagen, Valencia, CA). Filled red circles in Figure 1A indicate points maintained in 70 g/ml of Geneticin (GibcoBRL). To induce the expression
in the growth curve when mRNAs were isolated. The microarray experiments of COX-2 antisense, 2 g/ml doxycycline (Clontech) was added to the media
were performed at the National Institute of Environmental Health Sciences prior to the experiments.
Microarray Center (Research Triangle Park, NC). Detailed protocols for mi-
croarray procedures are available at http://dir.niehs.nih.gov/microarray. NS-398 inhibition
NS-398 (Cayman Chemical Company, Ann Arbor, MI) was dissolved in
Immunohistochemistry DMSO to generate 10 mM and 100 mM stock solutions. All final concentra-
Five-micron sections were cut from routinely fixed paraffin-embedded tissue tions of NS-398 used for the experiments were diluted in the same amount
blocks and mounted on SuperFrost Plus microscope slides (Fisher Scientific, of DMSO and made fresh for each usage. For two-dimensional culture,
Pittsburgh, PA). Specimens were stepwise deparaffinized in xylene and rehy- vHMEC were trypsinized and plated at a density of 2  104 cells per well
drated in descending alcohols. Endogenous peroxidase activity was blocked in a 6-well plate for exposure of cells to 0, 10, and 25 M and 5  104 per
by incubation in 3% hydrogen peroxide in methanol for 10 min. Sections well for cells exposed to 50M NS-398. HMEC were treated similarly, except
were microwaved for antigen retrieval for 10 min in a 10 mM citrate buffer 3.5  104 cells per well were plated for exposure to 50 M NS-398. NS-
(pH 6.0). Sections were rinsed in PBS and incubated for 30 min in blocking 398 was applied to cells 1 day after initial seeding and every other day
buffer (10% horse serum and 1% bovine serum albumin [BSA] in PBS), and thereafter via a media change. Cells were harvested on the sixth day, and
immunostaining was performed using a COX-2 specific anti-human mouse the numbers of live and total cells for each experiment were determined
monoclonal antibody (Cayman Chemical, No. 160112, Ann Arbor, MI) diluted using the trypan blue exclusion assay. Percent survival was calculated as
1:200 in 1% BSA in PBS overnight at 4	C. Control sections received human the number of live cells divided by the number of total cells in 0 M NS-
COX-2 control peptide (40 g/ml; Cayman Chemical) along with the COX-2 398 and adjusted according to the initial number of cells seeded. The relative
primary antibody (incubated for 1 hr prior to application). Sections were percent survival for cells in 0 M NS-398 was set to be 100%. The relative
rinsed in 0.05% Tween-20 in PBS followed by incubation in a biotinylated percent survival for cells in 10, 25, and 50 M were calculated as the ratio
IgG anti-mouse secondary (Vector Laboratories, No. BA-2000, Burlingame,
between the percent of survival at various NS-398 concentrations and the
CA) made in horse diluted 1:200 in 1% BSA in PBS. Slides were rinsed in
percent survival at 0 M NS-398. This experiment was done in triplicate for
PBS and incubated in avidin-biotin horseradish peroxidase complex (Vector
each of four sets of HMEC/vHMEC pairs. For 3D culture, HMEC/vHMEC
Laboratories, No. PK-6100, Vectastain Elite ABC kit) at a 1:100 dilution in
were trypsinized and suspended in Matrigel (BD Bioscience, Bedford, MA)
1% BSA in PBS for 30 min. Specimens were rinsed in 0.05% Tween-20 in
at a density of 5  104 cells/300 l. Cells were allowed to form 3D structures
PBS and incubated with 3,3
-diaminobenzadine (DAB) chromogenic sub-
for 10 days followed by exposure to 0, 50, and 100 M NS-398. Five days
strate (Sigma Chemical, No. D-5905, St. Louis, MO) for 4 min. Sections
after applying NS-398, cells were stained with propidium iodide (PI) without
were counterstained in hematoxylin, stepwise dehydrated through graded
fixation and imaged using IP lab image software.
alcohols, and cleared in xylene before mounting using permount.
TUNEL assayWestern blot analysis
TUNEL experiments were performed according to the manufacturer’s proto-Thirty micrograms of protein from total cell extracts was fractionated in
col from Clontech.gradient (4%–20%) polyacrylamide gels (FMC) and transferred to Hybond-P
(Amersham) membrane. Lysates were sequentially exposed to rabbit poly-
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